Document is current

Article History

Received: 9 January 2025

Accepted: 14 August 2025

First Online: 27 August 2025

Declarations

:

: All authors are employees of Hinge Bio, Inc. and each may hold shares in Hinge Bio, Inc. and/or have stock option agreements. D.J.C. is an inventor on patent applications related to this work (U.S. Application No. 17/373,751, “Tetrahedral Antibodies”; U.S. Application No. 18/153,840, “Tetrahedral Antibodies”; U.S. Application No. 18/188,412, Topologically Engineered Superdimeric Antibodies”; U.S. Application No. 18/949,940, “NK/Monocyte Engagers”; and “U.S. Application No. 19/050,008, “NK/Monocyte Engagers”) and a member of Biomolecular Holdings LLC, the assignee of the patent applications.

: All methods were carried out in accordance with the relevant local guidelines and regulations, and all experimental protocols were approved by the local institutional committees. All animal work was performed under study protocols reviewed and approved by University of Louisiana Lafayette’s Animal Care and Use Committee (IACUC) and in accordance with regulation of USDA animal welfare Act (CFR 9 Sects. 1,2,3). The studies were designed in accordance with ARRIVE guidelines. No human participants were directly involved with the study, while human samples were commercially purchased for in vitro experiments. Human PBMCs, healthy human whole blood, and SLE patient whole blood were obtained from BioIVT, Stanford Blood Center, and Cureline, respectively, with informed consent and approvals by Institutional Review Boards of BioIVT, Stanford Blood Center and Cureline, respectively.